Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Rat dog micro-cap picks... -- Ignore unavailable to you. Want to Upgrade?

To: tsigprofit who wrote (9792)	12/4/2002 10:55:34 AM
From: tsigprofit	Respond to of 48461

LDNA - more info - got idea off this other thread: Message 18296526 Lark Technologies, Inc.. The Company's principal activity is to provide contract molecular biology services to the pharmaceutical, biotechnology and agbio industries. The services provided by the Company are used worldwide by research organizations and drug development institutions to accelerate their efforts in bringing products to the market. The contract research service portfolio consists of over a hundred different molecular biology services in the areas of Nucleic Acid Extraction Services, DNA Sequencing Services, Genetic Stability Testing Services, Gene Expression and Detection Services and Custom Molecular Biology Services. The Company operates in the United States and the United Kingdom. Oct 31st Press Release: Lark Technologies Inc. Reports Fourth Consecutive Profitable Quarter and Record Nine Months EPS of $0.18 THURSDAY, OCTOBER 31, 2002 3:57 PM - BusinessWire HOUSTON, Oct 31, 2002 (BUSINESS WIRE) -- Lark Technologies Inc. (LDNA) today reported that revenues increased 23% to $1,571,620 in the third quarter of 2002 from revenues of $1,279,563 in the third quarter of 2001. For the nine months ending Sept. 30, 2002, revenues increased 14% to $4,963,686 from revenues of $4,359,355 in 2001. The increase in revenue during the quarter over the comparable period in 2001 was the result of increased sales across our core sequencing and genetic stability testing services. Net income from operations in the third quarter of 2002 was $153,707 or earnings per share of $0.04, reflecting an increase of $0.05 for the quarter compared with prior year earnings per share of ($0.01). Net income from operations increased $201,052 compared with prior year earnings of ($47,345). Earnings per share for the nine months ending Sept. 30, 2002 were $0.18 per share compared to ($0.07) per share in the same period of 2001. Trailing twelve month financial highlights include revenues of $6,644,796, operating income of $1,021,526, earnings per share of $0.26, and an annual Return on Shareholder's Equity (ROE) of 73%. Thus far in 2002, Lark has invested over $1.1 million in capital equipment to meet increased demand for its services. Commenting on the financial results, Lark Technologies Inc. Chief Executive Officer Carl W. Balezentis, Ph.D. said, "While we incurred some additional costs during the quarter that resulted in a slightly lower earnings per share, we are still on target for our earnings target for the year. We feel that we still have room for improvement in our gross margins and net income over the next year." Lark Technologies Inc., based in Houston, Texas, offers genomic services for use in pharmaceutical, diagnostic and agricultural product research and development. These services include genomic data management, microarray support, quantitative PCR, genotyping, genetically-modified organism testing, and a battery of other molecular biology services which support researchers in the pharmaceutical, biotechnology and academic sectors in their attempt to understand the mechanisms of disease and to discover and develop new drugs. Lark's stock is quoted on the OTC Bulletin Board under the symbol "LDNA.OB". Matt